Roivant gets global rights to Ligand's Type II diabetes candidate; deal terminated
Ligand Pharmaceuticals Inc. licensed Roivant Sciences GMBH exclusive worldwide rights to develop, manufacture, and commercialize its diabetes candidate LGD6972.
- Specialty Pharmaceuticals
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com